x
Filter:
Filters applied
- Opioids
- irritable bowel syndromeRemove irritable bowel syndrome filter
- FDARemove FDA filter
Publication Date
Please choose a date range between 2018 and 2019.
Opioids
2 Results
- Thematic review on gastroenterological diseases
Chronic Constipation
Mayo Clinic ProceedingsVol. 94Issue 11p2340–2357Published online: May 1, 2019- Adil E. Bharucha
- Arnold Wald
Cited in Scopus: 72Constipation is a common symptom that may be primary (idiopathic or functional) or associated with a number of disorders or medications. Although most constipation is self-managed by patients, 22% seek health care, mostly to primary care physicians (>50%) and gastroenterologists (14%), resulting in large expenditures for diagnostic testing and treatments. There is strong evidence that stimulant and osmotic laxatives, intestinal secretagogues, and peripherally restricted μ-opiate antagonists are effective and safe; the lattermost drugs are a major advance for managing opioid-induced constipation. - Thematic Review Series on Gastroenterological Diseases
Management Options for Irritable Bowel Syndrome
Mayo Clinic ProceedingsVol. 93Issue 12p1858–1872Published in issue: December, 2018- Michael Camilleri
Cited in Scopus: 47Irritable bowel syndrome (IBS) is associated with diverse pathophysiologic mechanisms. These mechanisms include increased abnormal colonic motility or transit, intestinal or colorectal sensation, increased colonic bile acid concentration, and superficial colonic mucosal inflammation, as well as epithelial barrier dysfunction, neurohormonal up-regulation, and activation of secretory processes in the epithelial layer. Novel approaches to treatment include lifestyle modification, changes in diet, probiotics, and pharmacotherapy directed to the motility, sensation, and intraluminal milieu of patients with IBS.